and now that we are at it [Bioanalytics]

posted by ElMaestro  – Denmark, 2018-11-05 18:19 (1052 d 08:36 ago) – Posting: # 19533
Views: 6,036

Hello nobody,

it is at the LLOQ the magic is needed. This is where the s:n is measured, also.

At present we have about 70 companies pursuing Tiotropium/Formoterol/Salmeterol/Fluticasone/and so forth approvals and for some of those methods we need an LLOQ of 0.1 pg/mL and not one iota less; even with the API6500 Qtrap and similar equipment this is at the border. The opportunity for assay optimizations have been exhausted (including columns, derivatization, SPE/LLE, and much mnore has been explored), the agency might not approve higher doses than a single shot per subject per period and we need to bear in mind that Cmax/LLOQ should be 20 or better.

You try and see if you can find a way to get approval for Tiotropium with e.g. 0.5 pg/mL. Good luck when meeting the agency :-D

So, in as much as I agree with you that LLOQ should not ever be an issue, LLOQ is a persistent issue. But of course, that really isn't what this thread is all about :-)

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,691 posts in 4,534 threads, 1,541 registered users;
online 3 (0 registered, 3 guests [including 3 identified bots]).
Forum time: Thursday 03:55 CEST (Europe/Vienna)

Learning is a lifetime process, but there comes a time
when we must stop adding and start updating.    Robert Brault

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5